News | August 02, 2024
GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr
Strong topline growth driven by solid performance across key brands.
Strong topline growth driven by solid performance across key brands.
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Abhay Soi, who had paid an income tax of approximately Rs 400 crore in the assessment year 2023-24 has been recognised as the “Top Individual tax payers having gross tax payable > Rs 10 Lakhs"
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Subscribe To Our Newsletter & Stay Updated
